CTVA vs GNVR vs BIOX Stock Comparison

Corteva, Genvor and Bioceres Crop Solutions Prices as of Nov 13, 2026 Peers: Industry group
1 more company in this comparison (NTR) Create a free account to keep reading and compare up to 10 companies.
CTVA Corteva, Inc.
$9.43 -29.6% 1M -85.8% 1Y
Market cap
$5.99B
P/E
7.9x
Revenue (TTM)
$17.65B
Div. yield
–
Crop Protection and Seeds Basic Materials
6 wins
GNVR Genvor Inc
$0.75 -16.7% 1M -61.5% 1Y
Market cap
$27.31M
P/E
–
Revenue (TTM)
—
Div. yield
–
Crop Protection and Seeds Basic Materials
1 win

Head to Head

10 decided of 12

Corteva leads on 6 of the 12 questions below (Corteva 6, Bioceres Crop Solutions 3, Genvor 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionCTVAGNVRBIOXLeader
Larger companyMarket capitalisation $5.99B $27.31M $13.05M CTVA
Cheaper on earningsLower P/E, profitable companies only 7.9x -7.8x -0.1x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS 15.5x — 4.2x BIOX
Faster revenue growthRevenue growth, trailing twelve months +1.0% — -12.0% CTVA
More profitableNet margin, trailing twelve months 4.3% — -92.3% CTVA
Better return on capitalReturn on invested capital 7.1% — -7.8% CTVA
Less leveragedLower net debt / EBITDA 0.8x — -21.6x BIOX
Higher dividend yieldTrailing dividend yield 0.00% — 0.00% –
Better 1-year returnPrice return, last 12 months -85.8% -61.5% -87.7% GNVR
Better 5-year returnAnnualised price return, 5 years -28.0%/yr — -57.3%/yr CTVA
Less volatileAnnualised volatility, 1 year 187.9% 280.2% 104.3% BIOX
Higher overall scoreMean of the five percentile scores vs peers 65/100 14/100 22/100 CTVA

Percentile Scorecard

CTVAGNVRBIOX

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisCTVAGNVRBIOX
Valuation 98 #3 of 96 12 #85 of 96 56 #43 of 96
Growth 42 #54 of 92 28 #67 of 92 0 #92 of 92
Profitability 53 #42 of 89 – 23 #69 of 89
Financial Health 58 #41 of 96 1 #95 of 96 8 #88 of 96
Shareholder Returns 72 #23 of 79 17 #66 of 79 –
Overall 65 14 22
  • CTVA ranked among 99 companies in Chemicals
  • GNVR ranked among 99 companies in Chemicals
  • BIOX ranked among 99 companies in Chemicals

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodCTVAGNVRBIOXSPY
1 month -29.6%-16.7%-30.0% -2.0%
3 months -87.7%+36.4%-53.3% -2.8%
6 months -88.5%+50.0%-51.2% +2.0%
Year to date -85.9%-25.0%-84.0% +10.6%
1 year -85.8%-61.5%-87.7% +12.2%
3 years -79.6%—-98.1% +68.1%
3 years, per year -41.2%—-73.3% +18.9%
5 years -80.6%—-98.6% +61.4%
5 years, per year -28.0%—-57.3% +10.1%

Risk

MeasureCTVAGNVRBIOXSPY
Volatility, 1Y 187.9%280.2%104.3% 13.6%
Downside volatility, 1Y 275.9%465.6%123.3% 13.9%
Beta vs S&P 500, 1Y -0.01-0.562.17 1.00
Return / volatility, 1Y -0.46-0.22-0.84 0.90
Max drawdown, 5Y -89.8%-97.5%-98.7% -25.4%
From 52-week high -89.6%-62.5%-87.8% -3.2%
52-week high $90.53$2.00$1.72 $779.14
52-week low $9.19$0.20$0.21 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleCTVAGNVRBIOX
P/E now vs peer median 8.3xmedian 23.4x -7.8xmedian 23.4x -0.1xmedian 23.4x
P/S now vs peer median 0.4xmedian 1.3x —median 1.3x 0.1xmedian 1.3x
EV/EBITDA now vs peer median 2.1xmedian 12.7x —median 12.7x -24.2xmedian 12.7x
P/FCF now vs peer median 10.3xmedian 17.0x -25.9xmedian 17.0x 0.2xmedian 17.0x
P/B now vs peer median 0.3xmedian 1.5x -10.1xmedian 1.5x 0.4xmedian 1.5x
PEG now vs peer median -1.69median 1.72 0.73median 1.72 0.00median 1.72

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsCTVAGNVRBIOX
Revenue $17.65B – $246.31M
Gross profit $8.77B – $88.12M
Operating income $3.43B -$4.01M -$23.41M
Net income $771.00M -$3.45M -$159.92M
Free cash flow $610.00M -$1.05M –
R&D $1.54B $386.20K –
EPS (diluted) $1.13 $-0.10 $-3.57
Cash & equivalents $3.93B $196.52K $11.24M
Total debt $7.45B $365.94K $121.84M
Shares (diluted) 670.70M 36.08M 63.65M
Enterprise value -$6.81B $26.88M -$450.57M

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricCTVAGNVRBIOX
P/E 8.3x -7.8x -0.1x
P/FCF 10.3x -25.9x 0.2x
P/Operating cash flow 13.2x -25.9x –
P/S 0.4x – 0.1x
P/B 0.3x -10.1x 0.4x
P/Tangible book 0.4x -10.1x -0.3x
EV/EBITDA 2.1x – -24.2x
EV/EBIT 2.9x -6.9x -5.3x
EV/Revenue 0.6x – 0.5x
EV/FCF 16.1x -26.1x –
EV/Operating cash flow 20.6x -26.1x –
PEG (3Y EPS CAGR) -1.69 0.73 0.00

Growth

14 metrics
MetricCTVAGNVRBIOX
Revenue growth (1Y) 1.0% – -12.0%
Revenue CAGR (3Y) 0.6% – -16.3%
Gross profit growth (1Y) 8.9% – -22.9%
Gross profit CAGR (3Y) 6.4% – -21.8%
Operating income growth (1Y) 12.7% 33.3% -279.5%
Operating income CAGR (3Y) 9.7% -55.6% -34.5%
Net income growth (1Y) -52.3% 41.0% -172.6%
Net income CAGR (3Y) -6.6% -38.4% -113.1%
EPS growth (1Y) -52.1% 55.1% -307.4%
EPS CAGR (3Y) -4.9% -10.7% -141.1%
Operating cash flow growth (1Y) -85.8% -151.3% –
Operating cash flow CAGR (3Y) 1.7% 1.7% –
Free cash flow growth (1Y) -78.3% -151.3% –
Free cash flow CAGR (3Y) 99.4% 1.7% –

Profitability

14 metrics
MetricCTVAGNVRBIOX
Gross margin 49.7% – 35.8%
EBITDA margin 26.5% – -2.1%
Operating margin 19.4% – -9.5%
Pretax margin 7.7% – -22.0%
Net margin 4.3% – -92.3%
FCF margin 3.5% – –
Operating cash flow margin 2.7% – –
Return on equity 3.1% – -374.4%
Return on assets 1.8% -1,412% -48.1%
Return on invested capital 7.1% – -7.8%
Return on capital employed 11.1% – -10.7%
Asset turnover 0.4x – 0.5x
Cash conversion (OCF / net income) 0.6x 0.3x –
Stock comp / revenue – – 0.2%

Financial Health

11 metrics
MetricCTVAGNVRBIOX
Debt / assets 17.3% 117.2% 27.2%
Debt / equity 0.3x -0.1x 3.6x
Net debt / EBITDA 0.8x – -21.6x
Debt / FCF 12.2x -0.3x –
Liabilities / assets 43.1% 969.3% 92.4%
Equity / assets 56.9% -869.3% 7.6%
Interest coverage 16.8x -37.1x –
Current ratio 1.6x 0.1x 0.8x
Quick ratio 1.0x 0.1x 0.5x
Cash ratio 0.3x 0.1x 0.0x
Altman Z-score 1.07 – –

Shareholder Returns

7 metrics
MetricCTVAGNVRBIOX
Dividend yield 7.6% – –
Net buyback yield -4.0% -2.8% –
Shareholder yield 3.7% -2.8% –
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusCTVAGNVRBIOX
Forward P/E 15.5xFY2026 – 4.2xFY2027
EPS, next fiscal year $0.61FY2026 – $0.05FY2027
EPS growth, next FY +22.0%FY2026 – –
EPS growth, the year after +14.8% – +1,040.0%
Revenue, next fiscal year $16.22BFY2026 – $395.84MFY2027
Revenue growth, next FY -6.8%FY2026 – +66.1%FY2027
Revenue growth, the year after -51.9% – +21.3%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersCTVAGNVRBIOX
Held by institutions 88.8% – 13.2%
Institutions holding 1,483 – 28
Change in shares held, QoQ +2.9% – -8.9%
Institutions buying 649 – 9
Institutions selling 527 – 6
Buyers to sellers 1.23 – 1.50

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

CTVAGNVRBIOX
CTVA 1.00 0.01 0.00
GNVR 0.01 1.00 -0.08
BIOX 0.00 -0.08 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, CTVA, GNVR and BIOX?

Corteva (CTVA) is the largest by market capitalisation: Corteva (CTVA) $5.99B, Genvor (GNVR) $27.31M, Bioceres Crop Solutions (BIOX) $13.05M.

Which company is growing faster?

Corteva (CTVA) grew revenue fastest over the trailing twelve months: Corteva (CTVA) +1.0%, Bioceres Crop Solutions (BIOX) -12.0%.

Which company is more profitable?

Corteva (CTVA) has the highest net margin (Corteva (CTVA) 4.3%, Bioceres Crop Solutions (BIOX) -92.3%). On return on invested capital, Corteva (CTVA) leads (Corteva (CTVA) 7.1%, Bioceres Crop Solutions (BIOX) -7.8%).

Which stock has performed better?

Over the past year Genvor (GNVR) returned the most: Corteva (CTVA) -85.8%, Genvor (GNVR) -61.5%, Bioceres Crop Solutions (BIOX) -87.7%. Over five years, Corteva (CTVA) compounded fastest (Corteva (CTVA) -28.0%/yr, Bioceres Crop Solutions (BIOX) -57.3%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Bioceres Crop Solutions (BIOX) has been the steadiest (Corteva (CTVA) 187.9%, Genvor (GNVR) 280.2%, Bioceres Crop Solutions (BIOX) 104.3%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, CTVA, GNVR and BIOX?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Corteva (CTVA) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.